Cargando…

Targeting Tregs in Malignant Brain Cancer: Overcoming IDO

One of the hallmark features of glioblastoma multiforme (GBM), the most common adult primary brain tumor with a very dismal prognosis, is the accumulation of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs). Regulatory T cells (Tregs) segregate into two primary categories: thymus-derived natural Tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wainwright, Derek A., Dey, Mahua, Chang, Alan, Lesniak, Maciej S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654236/ https://www.ncbi.nlm.nih.gov/pubmed/23720663 http://dx.doi.org/10.3389/fimmu.2013.00116

Ejemplares similares

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
por: Zhai, Lijie, et al.
Publicado: (2020)

The IDO–AhR Axis Controls Th17/Treg Immunity in a Pulmonary Model of Fungal Infection
por: de Araújo, Eliseu Frank, et al.
Publicado: (2017)

Current Challenges for IDO2 as Target in Cancer Immunotherapy
por: Mondanelli, Giada, et al.
Publicado: (2021)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma
por: Wainwright, Derek A, et al.
Publicado: (2014)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

IL-10(−/−) Enhances DCs Immunity Against Chlamydia psittaci Infection via OX40L/NLRP3 and IDO/Treg Pathways
por: Li, Qiang, et al.
Publicado: (2021)

Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
por: Günther, Juliane, et al.
Publicado: (2019)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

IDO Expression in Cancer: Different Compartment, Different Functionality?
por: Meireson, Annabel, et al.
Publicado: (2020)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
por: Maharaj, Kamira, et al.
Publicado: (2022)

Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct
por: Söderlund, Johan, et al.
Publicado: (2010)

IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity
por: Lippens, Carla, et al.
Publicado: (2016)

Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells
por: Chang, Alan L, et al.
Publicado: (2015)

Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2022)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions
por: LIU, JUN, et al.
Publicado: (2015)

New Insights into IDO Biology in Bacterial and Viral Infections
por: Schmidt, Susanne V., et al.
Publicado: (2014)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
por: Zhao, Li-Ping, et al.
Publicado: (2023)

Treg: A Promising Immunotherapeutic Target in Oral Diseases
por: Zhang, Yujing, et al.
Publicado: (2021)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

ICOS(+) Tregs: A Functional Subset of Tregs in Immune Diseases
por: Li, Dan-Yang, et al.
Publicado: (2020)

Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity
por: Zhang, Yujuan, et al.
Publicado: (2020)

The Yin and Yang of Targeting KLRG1(+) Tregs and Effector Cells
por: Borys, Samantha M., et al.
Publicado: (2022)

Corrigendum: ICOS+ Tregs: A Functional Subset of Tregs in Immune Diseases
por: Li, Dan-Yang, et al.
Publicado: (2021)

Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
por: Schoenhals, Jonathan E., et al.
Publicado: (2018)

GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg
por: Xu, Keman, et al.
Publicado: (2018)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals
por: Grohmann, Ursula, et al.
Publicado: (2015)

Prognostic values of regulatory T cells (Tregs) and Treg-related genes in gastric cancer
por: Zheng, Liang, et al.
Publicado: (2023)

Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses
por: Christensen, Lanette M., et al.
Publicado: (2022)

Targeting Malignant Brain Tumors with Antibodies
por: Razpotnik, Rok, et al.
Publicado: (2017)

The Presence of IL-17A and T Helper 17 Cells in Experimental Mouse Brain Tumors and Human Glioma
por: Wainwright, Derek A., et al.
Publicado: (2010)

Treg Heterogeneity, Function, and Homeostasis
por: Shevyrev, Daniil, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_44rn0tril2qjahhgocquieaobb